Strange bedfellows: Bill Gates and Chairman Mao

News recently out of a discussion at the The Royal Society, London, is raising hopes that an effective and affordable cure for malaria is now on the horizon. But what do both Bill Gates and Chairman Mao have to do with this story? Well, plenty, if you follow the thread and history of malaria treatments.
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
This headline could be a severe case of six degrees of separation, but bear with me. News recently out of a discussion at the The Royal Society, London, is raising hopes that an effective and affordable cure for malaria is now on the horizon and could be making its way into patients' hands (and mouths) as early as 2010. What's more, this cure for malaria would also mark another milestone in world health, as it would be the first time synthetic biology—collections of synthetic genes that will control the fermentation and growth of yeast—is used to produce a medicine.

This breakthrough is courtesy of a research team led by University of California, Berkeley, Prof. Jay Keasling to insert as many as a dozen genes into yeast microbes that will effectively redesign and allow for growth of these microbes into artemisinin, a well-known cure for malaria. Currently derivatives of artemisinin that are used to produce malaria medicines are extracted from sweet wormwood (Artemisia annua), but the resulting medicine is relatively expensive—especially when we are talking a disease that is predominant in developing countries—at about 2 bucks a dose. Using the synthetic biology approach to production, where all the medicine needed would be produced in one huge 50,000-liter vat, could potentially provide this medicine at pennies on the dollar compared with current treatments.

With an estimated half-billion people afflicted with malaria each year, and as many as 2 million deaths annually—mostly young children—it's pretty easy to see how producing ample, cheap medicine to fight this disease is an important development in improving world health.

What's more, it should be possible, in theory, to continually re-engineer artemisinin, to combat drug resistant strains of malaria.

But what do both Bill Gates and Chairman Mao have to do with this story? Well, plenty, if you follow the thread and history of malaria treatments.

As it turns out, the Chinese have been effectively treating malaria for more than 15 centuries, using Artemisia annua as a natural remedy. More recently the ancient remedy was developed during Mao's Cultural Revolution—it was drunk as tea by the North Vietnamese Army and the Viet Cong­. But world politics being what they were and skepticism about the treatment itself, its spread and adoption by the West and the rest of the world was severely slowed.

Once it got out, though, artemisinin was recognized as the most effective treatment against the disease, and to date, the malaria parasite has not developed resistance to it.
Continue reading below...
A black mosquito is shown on pink human skin against a blurred green backdrop.
InfographicsDiscovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Read More

And that is where Bill Gates steps in. His philanthropic organization, The Bill and Melinda Gates Foundation, ponied up more than $40 million to Keasling's Berkeley lab, his company Amyris Biotechnologies and the One World Health Foundation to develop this treatment. It appears that investment is about to pay off.

So there you have it (with apologies to Prof. Keasling): Gates and Mao . . . malaria pioneers.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue